Table 1.

Summary of scenarios for future HIV funding decisions.

	No further program expansiona	Increased US fundingb	Increased US and domestic fundingc	Increased US and domestic funding with optimal allocationd
Total funding from all sources, 2017–2032	$81 billion	$116 billion	$146 billion	$146 billion
% of PLHIVe virally suppressed on treatment by 2032	28%	66%	77%	83%
Total HIV infections, 2017–2032	25 700 000	13 200 000	7 360 000	3 520 000
Total AIDS deaths, 2017–2032	4 360 000	3 330 000	2 460 000	2 040 000
New HIV infections in 2032	1 990 000	838 000	453 000	173 000
AIDS deaths in 2032	260 000	167 000	111 000	78 000

^aMaintenance of current numbers of people on treatment in all locations without further scaling up of coverage or introduction of new prevention interventions (Appendix pg. 8).

^bA 10% increase in yearly US funding from the present level, with other international contributions remaining flat at present levels and conservative domestic projections in which domestic public HIV spending in the modeled countries increases in line with economic growth (Appendix pg. 8–11).

^cA 10% increase in US funding, other international funding remaining flat, and ambitious domestic projections which see modeled countries boosting their HIV spending to match a benchmark based on the HIV share of the disease burden (Appendix pg. 11–12).

^dThe same overall budget as in the previous scenario (footnote 3), but with allocation to geographies, population groups, and interventions being responsive to local epidemiology (Appendix pg. 12).

^ePLHIV, people (adults age 15 and above) living with HIV.